|
|
|
|
|
|
 |
|
|
|
|
|
|
|
Anderton
MJ, Jukes R, Lamb JH, Manson MM, Gescher AJ, Steward WP, Williams ML
(2003)
Liquid chromatography assay for the simultaneous determination of
indole-3-carbinol and its acid condensation products in plasma. J.
Chromatog. 787: 281-291 |
|
|
|
|
|
|
|
Brown
K, Carmichael PL (2003) Correspondence
re: M Sharma et al., “Antioxidant inhibits tamoxifen-DNA adducts in
endometrial explant culture”. Biochem. Biophys. Res. Commun. 310: 1039
|
|
|
|
|
|
| |
|
Brown
K, Harvey CA, Turteltaub KW, Shields SJ (2003) Structural
characterization of carcinogen-modified oligodeoxynucleotide adducts
using matrix-assisted laser desorption/ionization mass spectrometry. J.
Mass Spectrom. 38, 68-79 |
|
|
|
|
|
|
|
Cai
H, Verschoyle RD, Steward WP, Gescher AJ (2003) Determination of the
flavone tricin in human plasma by high-performance liquid
chromatography. Biomed. Chromatog. 17: 435-439 |
|
|
|
|
|
|
|
Dalhoff
K, Dancey J, Astrup L, Skovsgaard T, Hamberg KJ, Lofts FJ, Rosmorduc O,
Erlinger S, Hansen JB, Steward WP, Skov T, Burcharth F, Evans TRJ (2003)
A phase II study of the vitamin D analogue Seocalcitol in
patients with inoperable hepatocellular carcinoma. Brit. J. Cancer
89: 252-257 |
|
|
|
|
|
| |
|
Donald
S, Verschoyle, RD, Edwards ER, Judah DJ, Davies R, Riley J, Dinsdale D,
Lopez-Lazaro LL, Smith AG, Gant TW, Greaves P, Gescher AJ (2002)
Hepatobiliary damage and changes in hepatic gene expression caused by
the antitumor drug ecteinascidin-743 (ET-743) in the female rat.
Cancer Res. 62: 4256-4262
|
|
|
|
|
|
| |
|
Donald
S, Verschoyle RD, Greaves P, Gant TW, Colombo T, Zaffaroni M, Frapolli
R, Zucchetti M, D'Incalci M, Meco D, Riccardi R, Lopez-Lazaro L, Jimeno
J, Gescher AJ (2003) Complete protection by high-dose dexamethasone
against the hepatotoxicity of the novel antitumor drug yondelis (ET-743)
in the rat. Cancer Res. 63: 5902-5908 |
|
|
|
|
|
| |
|
Farmer
PB, Bartsch H, Boobis A, Chipman K, Gescher A, Kadlubar FF, Manson MM,
Phillips DH, Shuker DEG, Swenberg JA, Tannenbaum SR, Wild CP (2002)
Basic or applied, it’s the interaction that counts. Nature 417, 117 |
|
|
|
|
|
| |
|
Fillingham,
Barsukov IG, Damblon CF, Gescher AJ, Roberts GCK (2003)
Synthesis of a simplified bryostatin C-ring analog that binds to
the CRD2 of human PKC-alpha, and construction of a novel BC-analog by an
unusual Julia olefination process. Org. Lett. 5: 499-50 | |
|
|
|
|
|
|
Garcea
G, Sharma RA, Dennison A, Steward WP, Gescher AJ, Berry DP (2003)
Molecular biomarkers of colorectal carcinogenesis and their role in
surveillance and early intervention. Europ. J. Cancer 39: 1041-1052 |
|
|
|
|
|
| |
|
Gescher
AJ, Steward WP (2003) Relationship between mechanisms, bioavailability,
and preclinical chemopreventive efficacy of resveratrol: A conundrum.
Cancer Epidemiol. Biomarkers & Prev. 12 : 953-957 | |
|
|
|
|
|
|
Gescher
AJ, Sharma RA, Steward WP (2003) Cancer prevention and delay are as
important as cure. Lancet Oncol. 4: 72-73 |
|
|
|
|
|
|
|
Howells
L, Gallacher-Horley B, Houghton CE, Manson MM, Hudson EA.
Indole-3-carbinol inhibits Akt/PKB and induces apoptosis in the
human breast tumor cell line MDA MB-468, but not in the non-tumorigenic
HBL-100 line (2002). Molec. Cancer Ther. 1, 1161-1172 |
|
|
|
|
|
|
|
Hudson
EA, Howells LM, Gallacher-Horley B, Fox LH, Gescher AJ, Manson MM (2003)
Growth-inhibitory effects of the chemopreventive agent indole-
3-carbinol are increased in combination with the polyamine putrescine in
the SW-480 colon tumour cell line. BMC Cancer 3: 9 |
|
|
|
|
|
|
|
Ireson
C, Jones DJL, Orr S, Coughtrie MWH,
Boocock D, Williams ML, Farmer PB, Steward WP, Gescher A (2002)
Metabolism of cancer chemopreventive agent curcumin in human and rat
intestine. Cancer Epidemiol
Biomarkers & Prev. 11: 97-104 |
|
|
|
|
|
| |
|
Lashley
MR, Dicus CW, Brown K, Nantz MH (2003) Synthesis of a-hydroxytamoxifen
and its 4-hydroxy analog. Org. Prep. Proced. Internat. 35: 231-238 |
|
|
|
|
|
|
|
Leong
CO, Gaskell M, Martin EA, Heydon RT, Farmer PB, Bibby MC, Cooper PA,
Double JA, Bradshaw TD, Stevens MFG (2003) Antitumour
2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour
cells in vitro and in vivo. Brit. J. Cancer 44: 369 |
|
|
|
|
|
|
|
Manson
MM (2003) Cancer prevention - The potential for diet to modulate
molecular signalling. Trends Molec. Med. 9:11-18 | |
|
|
| |
|
|
Martin
EA, Brown K, Gaskell M, Al-Azzawi F, Garner RC, Boocock DJ, Mattock E,
Pring DW, Dingley K, Turteltaub KW, Smith LL, White INH (2003) Tamoxifen
DNA damage detected in human endometrium using accelerator mass
spectrometry. Cancer Res. 63: 8461-8465 | |
|
|
| |
|
|
Morgan
B, Thomas BL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross
K, Ball HA, Lee L, Mietlowski W, Fuxius S, Unger C, O'Byrne K, Henry A,
Cherryman GR, Laurent D, Dugan M, Marme D, Steward WP (2003) Dynamic
contrast-enhanced magnetic resonance imaging as a biomarker for the
pharmacological response of PTK787/ZK 222584, an inhibitor of the
vascular endothelial growth factor receptor tyrosine kinases, in
patients with advanced colorectal cancer and liver metastases: Results
from two phase I studies. J Clin. Oncol. 21: 3955-3964 | |
|
|
| |
|
|
Perkins
S, Clarke AR, Steward WP, Gescher AJ (2003) Age-related difference in
susceptibility of ApcMin/+ mice towards the chemopreventive efficacy of
dietary aspirin and curcumin. Brit. J. Cancer 88: 1480-1483 | |
|
|
| |
|
|
Perkins
S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, Williams
ML, Steward WP, Gescher AJ (2002) Relationship between chemopreventive
efficacy and pharmacokinetics of curcumin in the Min/+ mouse, a model of
familial adenomatous polyposis. Cancer
Epidemiol Biomarkers & Prev. 11: 535-540. | |
|
|
| |
|
|
Potter
GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, Ruparella KC,
Lamb JH, Farmer PB, Stanley LA, Burke MD (2002) The cancer preventative
agent resveratrol is converted to the anticancer agent piceatannol by
the cytochrome P450 enzyme CYP1B1.
Brit. J. Cancer 86: 774-778 | |
|
|
| |
|
|
Ratan
HL, Gescher AJ, Steward WP, Mellon JK (2003) ErbB receptors: possible
therapeutic targets in prostate cancer? BJU Internat. 92: 890-895 | |
|
|
| |
|
|
Smith
LK, Botha JL, Benghiat A, Steward WP (2003) Latest trends in cancer
incidence among UK South Asians in Leicester. Brit. J. Cancer 89: 70-73 | |
|
|
| |
| |
|
Thomas
AL, Morgan B, Drevs J, Unger C, Wiedenmann B, Vanhoefer U, Laurent D,
Dugan M, Steward WP (2003) Vascular endothelial growth factor receptor
tyrosine kinase inhibitors: PTK787/ZK 222584. Seminars Oncol. 30: 32-38 | |
|
|
|
|
|
|
 |
|
|
